Results 1 to 10 of about 1,585 (112)

Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial

Journal of the Formosan Medical Association, 2022
Background/purpose: Roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor, promotes erythropoiesis and regulates iron metabolism.
Bing Li, Yan-Pei Hou
exaly   +3 more sources

Initial side effects of roxadustat on thyroid function in patients undergoing hemodialysis [PDF]

Renal Failure
Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is effective for treating renal anemia, with efficacy noninferior to erythropoiesis-stimulating agents. However, data on its adverse effects remain scarce. In medical practice,
Hideyuki Yamada, Rena Yuasa, Kiyoto Koibuchi, Moriatsu Miyagi, Ken Sakai   +4 more
doaj   +2 more sources

Effect of Roxadustat and Erythropoietin on Glycated Hemoglobin of Non-Dialysis Type 2 Diabetic Nephropathy Anemia Patients [PDF]

Biomedicines
Objectives: To investigate the effects of Roxadustat and recombinant human erythropoietin (rHuEPO) on glycemic control and glycated hemoglobin (HbA1c) in non-dialysis type 2 diabetic kidney disease (DKD) patients with anemia.
Zhouxia Xiang, Wenqian Wei, Shunian Guo, Hanyu Meng, Shu Rong   +4 more
doaj   +2 more sources

Influencing factors of clinical efficacy of roxadustat among hemodialysis patients

Renal Failure
Objective To explore independent influencing factors for clinical efficacy of roxadustat in hemodialysis patients.Methods Hemodialysis patients treated with roxadustat were enrolled.
Wenhui Wu
exaly   +3 more sources

Association of gut microbiome signatures with iron metabolism response to roxadustat in peritoneal dialysis patients with anemia: a cross-sectional study [PDF]

Frontiers in Pharmacology
BackgroundAnemia in chronic kidney disease (CKD) is associated with increased cardiovascular risk, impaired quality of life, and reduced survival.
Jiangqing Fan, Jiangqing Fan, Xinqi Tan, Ying Liu, Zhe Liu, Jialing Dai, Lulu Wang, Lulu Wang   +7 more
doaj   +2 more sources

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study

Renal Failure
Roxadustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, has proven efficacy in the treatment of renal anemia; however, evidence indicates that it may cause central hypothyroidism.
Mineaki Kitamura, Hiroshi Mukae, Satoshi Funakoshi   +2 more
exaly   +3 more sources

Sex-Specific Impact of Roxadustat on Residual Kidney Function in Peritoneal Dialysis Patients: A Propensity Score-Weighted Analysis [PDF]

Kidney Medicine
Rationale & Objective: Roxadustat effectively improves renal anemia, but its impact on residual kidney function (RKF) preservation in continuous ambulatory peritoneal dialysis (CAPD) patients is unclear.
Simin Jiang, Guanji Zhang, Yiping Xu, Yi Li, Guanglan Li, Hongyu Li, Yuchu Liu, Siyuan Li, Jianxiong Lin, Qunying Guo, Xiao Yang, Wei Chen, Haiping Mao, Yating Wang   +13 more
doaj   +2 more sources

Impact of roxadustat on anemia management in infected patients undergoing long-term dialysis: a retrospective cohort analysis [PDF]

Frontiers in Pharmacology
IntroductionThe efficacy of oral roxadustat in dialysis patients with renal anemia and overt infections remains uncertain.ObjectivesIn this retrospective cohort study, 2816 such patients were screened, of whom 167 were enrolled and assigned to either ...
Lulu Wang, Lulu Wang, Huimin Qiu, Xinqi Tan, Jing Liu, Ting Yang, Chunming Jiang, Chunming Jiang   +7 more
doaj   +2 more sources

Roxadustat promotes osteoblast differentiation and prevents estrogen deficiency-induced bone loss by stabilizing HIF-1α and activating the Wnt/β-catenin signaling pathway

Journal of Orthopaedic Surgery and Research, 2022
Background Osteoporosis is a very common skeletal disorder that increases the risk of fractures. However, the treatment of osteoporosis is challenging. Hypoxia-inducible factor-1α (HIF-1α) plays an important role in bone metabolism. Roxadustat is a novel
Luyao Li, Afang Li, Li Zhu, Liangying Gan, Li Zuo   +4 more
doaj   +1 more source

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis

Renal Failure, 2022
Background Both early correction of anemia and preserving residual renal function (RRF) are reported to improve patient survival. The aim of this study was to explore the efficacy and safety of Roxadustat for treatment of renal anemia in patients new to ...
Tong Wu, Yuanyuan Qi, Shuang Ma, Lijie Zhang, Xinyu Pu, Kui Chen, Ying Zhao, Shenghua Sang, Jing Xiao   +8 more
doaj   +1 more source